BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33109568)

  • 1. High Expression of UBE2B as a Poor Prognosis Factor in Patients With Rectal Cancer Following Chemoradiotherapy.
    Huang WL; Luo CW; Chou CL; Yang CC; Chen TJ; Li CF; Pan MR
    Anticancer Res; 2020 Nov; 40(11):6305-6317. PubMed ID: 33109568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy.
    Li CF; He HL; Wang JY; Huang HY; Wu TF; Hsing CH; Lee SW; Lee HH; Fang JL; Huang WT; Chen SH
    J Clin Pathol; 2014 Dec; 67(12):1056-61. PubMed ID: 25271212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High EREG Expression Is Predictive of Better Outcomes in Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy.
    Lin CY; Hsieh PL; Chou CL; Yang CC; Lee SW; Tian YF; Shiue YL; Li WS
    Oncology; 2020; 98(8):549-557. PubMed ID: 32408308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
    He HL; Lee YE; Chen HP; Hsing CH; Chang IW; Shiue YL; Lee SW; Hsu CT; Lin LC; Wu TF; Li CF
    Exp Mol Pathol; 2015 Jun; 98(3):338-45. PubMed ID: 25805104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy.
    Sheu MJ; Li CF; Lin CY; Lee SW; Lin LC; Chen TJ; Ma LJ
    Tumour Biol; 2014 Aug; 35(8):7755-63. PubMed ID: 24810927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of REG4 confers an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.
    He HL; Lee YE; Shiue YL; Lee SW; Lin LC; Chen TJ; Wu TF; Hsing CH; Huang HY; Wang JY; Li CF
    J Surg Oncol; 2014 Dec; 110(8):1002-10. PubMed ID: 25155043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The X-linked inhibitor of apoptosis protein is an independent prognostic marker for rectal adenocarcinoma after preoperative chemoradiotherapy.
    Chen YT; Tsao SC; Tsai HP; Wang JY; Chai CY
    Virchows Arch; 2016 May; 468(5):559-67. PubMed ID: 26915033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low BRCA2 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy.
    Sheu MJ; Chou CL; Yang CC; Lee SW; Tian YF; Lin CY; Hsiao SY; Chen SH; Huang WT
    Pathol Res Pract; 2020 May; 216(5):152922. PubMed ID: 32249003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of high ubiquitin-conjugating enzyme E2 expression as a prognostic factor in nasopharyngeal carcinoma.
    Kao WC; Hsu SH; Lin CL; Lin CY; Chen SW; Chen YX; Chen CH; Lee SW; Tsao CJ; Huang WT; Chen SH; Hsiao SY
    Oncol Lett; 2022 Jun; 23(6):194. PubMed ID: 35572494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. REG3A overexpression functions as a negative predictive and prognostic biomarker in rectal cancer patients receiving CCRT.
    Li WS; Chen TJ; Lee SW; Yang CC; Tian YF; Kuo YH; Tsai HH; Wu LC; Yeh CF; Shiue YL; Chou CL; Lai HY
    Histol Histopathol; 2024 Jan; 39(1):91-104. PubMed ID: 37042618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
    Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
    Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative endoscopic tattooing technique improved lymph node retrieval in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy.
    Chen YT; Wang JY; Wang JW; Chai CY
    J Clin Pathol; 2020 May; 73(5):267-272. PubMed ID: 31690565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy.
    Lee YE; He HL; Shiue YL; Lee SW; Lin LC; Wu TF; Chang IW; Lee HH; Li CF
    Tumour Biol; 2015 Sep; 36(10):7675-83. PubMed ID: 25929810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PLA2G2A overexpression is associated with poor therapeutic response and inferior outcome in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy.
    He HL; Lee YE; Shiue YL; Lee SW; Lin LC; Chen TJ; Wu TF; Li CF
    Histopathology; 2015 Jun; 66(7):991-1002. PubMed ID: 25393083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BMI1-KLF4 axis deficiency improves responses to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
    Hsu YC; Luo CW; Huang WL; Wu CC; Chou CL; Chen CI; Chang SJ; Chai CY; Wang HC; Chen TY; Li CF; Pan MR
    Radiother Oncol; 2020 Aug; 149():249-258. PubMed ID: 32592893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High chloride channel accessory 1 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy.
    Chen TJ; He HL; Shiue YL; Yang CC; Lin LC; Tian YF; Chen SH
    Int J Med Sci; 2018; 15(11):1171-1178. PubMed ID: 30123054
    [No Abstract]   [Full Text] [Related]  

  • 17. Multidrug resistance-associated protein 3 confers resistance to chemoradiotherapy for rectal cancer by regulating reactive oxygen species and caspase-3-dependent apoptotic pathway.
    Yu Z; Zhang C; Wang H; Xing J; Gong H; Yu E; Zhang W; Zhang X; Cao G; Fu C
    Cancer Lett; 2014 Oct; 353(2):182-93. PubMed ID: 25088576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficiency in asparagine synthetase expression in rectal cancers receiving concurrent chemoradiotherapy: negative prognostic impact and therapeutic relevance.
    Lin CY; Sheu MJ; Li CF; Lee SW; Lin LC; Wang YF; Chen SH
    Tumour Biol; 2014 Jul; 35(7):6823-30. PubMed ID: 24729124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of Dehydrogenase/Reductase 9 Predicts Poor Response to Concurrent Chemoradiotherapy and Poor Prognosis in Rectal Cancer Patients.
    Chen TJ; Hsu BH; Lee SW; Yang CC; Tian YF; Kuo YH; Li WS; Tsai HH; Wu LC; Yeh CF; Chou CL; Lai HY
    Pathol Oncol Res; 2022; 28():1610537. PubMed ID: 36277959
    [No Abstract]   [Full Text] [Related]  

  • 20. 53BP1 expression and immunoscore are associated with the efficacy of neoadjuvant chemoradiotherapy for rectal cancer.
    Huang A; Xiao Y; Peng C; Liu T; Lin Z; Yang Q; Zhang T; Liu J; Ma H
    Strahlenther Onkol; 2020 May; 196(5):465-473. PubMed ID: 31828392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.